PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1618302
PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1618302
Exocrine Pancreatic Insufficiency Treatment Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 - 2032
The Global Exocrine Pancreatic Insufficiency Treatment Market reached USD 2.7 billion in 2023, with a projected growth rate of 5.6% CAGR from 2024 to 2032. Exocrine pancreatic insufficiency, characterized by a lack of pancreatic enzymes critical for nutrient digestion and absorption, is managed through a combination of medical and dietary approaches. Treatment strategies for EPI aim to reduce symptoms, boost nutrient absorption, and improve the quality of life for those affected by the condition. Significant advancements in diagnostic techniques for EPI are improving detection and supporting more timely, effective treatments. Latest research has aimed at detecting definite biomarkers, which are transforming pancreatic function assessments and facilitating earlier diagnosis.
Fecal elastase-1 has emerged as an essential biomarker, with low levels indicating pancreatic insufficiency, enhancing diagnostic precision and contributing to market expansion. The market is segmented by treatment type into nutritional management and pancreatic enzyme replacement therapy (PERT), with the PERT segment leading in market revenue, reaching USD 2.3 billion in 2023. PERT aids in restoring the body's ability to digest essential nutrients, alleviating common symptoms such as bloating and steatorrhea. By enabling proper absorption of fats, proteins, and carbohydrates, PERT prevents complications associated with EPI, including malnutrition, vitamin deficiencies, and unintended weight loss, significantly improving patients' quality of life. In terms of drug types, the market includes key medications designed for PERT, each offering unique formulations to enhance nutrient absorption and relieve symptoms associated with EPI.
With enzymes like lipase, protease, and amylase, these therapies are optimized for efficiency, utilizing enteric-coated capsules to ensure enzymes are effectively released in the small intestine where digestion occurs. These formulations are available in various dosages, allowing for treatment customization based on individual patient requirements. North America accounted for a major share of the EPI treatment market in 2023, with an anticipated growth reaching USD 2.4 billion by 2032. The region benefits from advanced healthcare infrastructure, extensive research initiatives, and broad access to PERT, driving growth in EPI treatment availability. Additionally, comprehensive insurance coverage and well-established healthcare systems in North America enhance patient access to specialized medications and care, further supporting market expansion and improved patient outcomes.As advancements in diagnostic methods and therapeutic options continue to evolve, the global EPI treatment market is expected to see steady growth.
| Market Scope | |
|---|---|
| Start Year | 2023 |
| Forecast Year | 2024-2032 |
| Start Value | $2.7 Billion |
| Forecast Value | $4.4 Billion |
| CAGR | 5.6% |
Table of Contents
Chapter 1 Methodology & Scope
- 1.1 Market scope & definition
- 1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
- 1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
- 1.4 Forecast model
- 1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources
Chapter 2 Executive Summary
- 2.1 Industry 360° synopsis
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Increasing prevalence of chronic pancreatitis (CP) and cystic fibrosis
- 3.2.1.2 Growing aging population
- 3.2.1.3 Advancements in diagnosis
- 3.2.1.4 Technological advancements in pharmaceutical industry
- 3.2.2 Industry pitfalls & challenges
- 3.2.2.1 High cost of treatment
- 3.2.2.2 Limited awareness and education
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Regulatory landscape
- 3.5 Technology landscape
- 3.6 Pipeline analysis
- 3.7 Porter's analysis
- 3.8 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
- 4.1 Introduction
- 4.2 Company market share analysis
- 4.3 Competitive positioning matrix
- 4.4 Strategy outlook matrix
Chapter 5 Market Estimates and Forecast, By Treatment, 2021 - 2032 ($ Mn)
- 5.1 Key trends
- 5.2 Nutritional management
- 5.3 Pancreatic enzyme replacement therapy (PERT)
Chapter 6 Market Estimates and Forecast, By Drug Type, 2021 - 2032 ($ Mn)
- 6.1 Key trends
- 6.2 Creon
- 6.3 Zenpep
- 6.4 Pancreaze
- 6.5 Viokace
- 6.6 Other drug types
Chapter 7 Market Estimates and Forecast, By Symptom, 2021 - 2032 ($ Mn)
- 7.1 Key trends
- 7.2 Abdominal pain
- 7.3 Constipation
- 7.4 Diarrhea
- 7.5 Fatty stools
- 7.6 Weight loss
- 7.7 Other symptoms
Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)
- 8.1 Key trends
- 8.2 Hospital pharmacies
- 8.3 Retail pharmacies
- 8.4 Online pharmacies
Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)
- 9.1 Key trends
- 9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
- 9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
- 9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
- 9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE
Chapter 10 Company Profiles
- 10.1 Abbott Laboratories
- 10.2 AbbVie
- 10.3 Digestive Care
- 10.4 Essential Pharma
- 10.5 Nestle
- 10.6 Nordmark Pharma
- 10.7 Sun Pharmaceutical Industries
- 10.8 Viatris
- 10.9 Vivus
- 10.10 Zentiva Pharma UK
